Bulletin Du Cancer最新文献

{"title":"Real-world efficacy and toxicity of the LMBA02 protocol for Burkitt lymphoma in Morocco","authors":"Sophia Berrada ,&nbsp;Sara Naim ,&nbsp;Samira Benayad ,&nbsp;Amine Benmoussa ,&nbsp;Mouna Lamchahab ,&nbsp;Rachid Mohamed ,&nbsp;Abdellah Madani ,&nbsp;Meryem Qachouh","doi":"10.1016/j.bulcan.2025.02.018","DOIUrl":"10.1016/j.bulcan.2025.02.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Burkitt lymphoma (BL) is a highly aggressive B cell lymphoma that accounts for 1 to 5% of cases in Western Europe. In France, the LMBA02 protocol has shown promising overall survival (OS) and event-free survival (EFS) rates, with 83 and 75% respectively for patients receiving rituximab. In Morocco, the LMBA02 regimen is used for BL treatment.</div></div><div><h3>Methods</h3><div>In this study, we aimed to retrospectively analyze the real-world efficacy and toxicity of the LMBA02 protocol in daily clinical practice. We conducted a retrospective monocentric study on adult patients aged 18<!--> <!-->years and above, newly diagnosed with BL between 2010 and 2019, and treated with the LMBA02 protocol at the hematology center of the 20 Août 1953 hospital in Casablanca.</div></div><div><h3>Results</h3><div>A total of 63 patients were newly diagnosed with BL, of which 58 patients were evaluable. The average duration of treatment was 19<!--> <!-->weeks (14–28) for group B patients and 37.5<!--> <!-->weeks (26–48) for group C patients. Among the patients, 33 (56%) achieved a complete response (CR) at the end of treatment. Four patients relapsed. Eleven patients died due to treatment toxicity, resulting in a treatment-related mortality rate (TRM) of 19%. The estimated 5-year EFS and OS rates for all 63 patients were 54 and 69%, respectively. Notably, the 5-year overall survival estimates for groups B and C were 77 and 46% (<em>P</em> <!-->=<!--> <span>0.02) respectively. Univariate analysis of OS for the 63 patients revealed that a low serum LDH level (</span><em>P</em> <!-->=<!--> <!-->0.009) and receiving rituximab (<em>P</em> <!-->=<!--> <!-->0.006) were associated with significantly better 5-year OS.</div></div><div><h3>Discussion</h3><div>Key findings from this analysis include comparable survival rates in adults with BL compared to previous real-life studies, a significant and high TRM rate, and a survival benefit associated with rituximab treatment.</div></div><div><h3>Introduction</h3><div>Le lymphome de Burkitt (LB) est un lymphome B hautement agressif représentant 1 à 5 % des cas en Europe occidentale. En France, le protocole LMBA02 a montré des taux prometteurs de survie globale et de survie sans événement, atteignant respectivement 83 et 75 % chez les patients traités avec rituximab. Au Maroc, le protocole LMBA02 est utilisé pour traiter ces patients. Cette étude a pour objectif d’analyser l’efficacité et la toxicité du protocole LMBA02 dans la pratique clinique quotidienne.</div></div><div><h3>Patients et méthodes</h3><div>Nous avons mené une étude rétrospective monocentrique sur des patients adultes (âgés de 18 ans et plus) nouvellement diagnostiqués avec un lymphome de Burkitt entre 2010 et 2019 et traités selon le protocole LMBA02 au service d’hématologie de l’hôpital 20 Août 1953 à Casablanca.</div></div><div><h3>Résultats</h3><div>Un total de 63 patients ont été diagnostiqués, dont 58 étaient évaluables. La d","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages 961-968"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommandations du Comité neuroblastome de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent pour la prise en charge des patients présentant un neuroblastome de haut risque en rechute/progression","authors":"Pablo Berlanga ,&nbsp;Claudia Pasqualini ,&nbsp;Marion Gambart ,&nbsp;Benoit Dumont ,&nbsp;Estelle Thebaud ,&nbsp;Julie Tandonnet ,&nbsp;Joy Benadiba ,&nbsp;Amaury Leruste ,&nbsp;Carole Coze ,&nbsp;Gudrun Schleiermacher ,&nbsp;Anne Sophie Defachelles","doi":"10.1016/j.bulcan.2025.04.006","DOIUrl":"10.1016/j.bulcan.2025.04.006","url":null,"abstract":"<div><div>Le pronostic des patients porteurs d’un neuroblastome de haut risque en rechute ou progression après une première ligne de traitement reste sombre. Cependant, au cours de la dernière décennie, le développement de nouvelles thérapies donne aux médecins, familles et patients l’espoir de meilleures chances de contrôle tumoral et, dans quelques cas, de guérison. Compte tenu de l’évolution rapide de ces nouvelles modalités thérapeutiques dans ce contexte, les dossiers de ces patients doivent impérativement être discutés lors de réunions de concertation pluridisciplinaires afin de proposer au patient et à sa famille l’option thérapeutique la plus adaptée à l’état actuel des connaissances. Nous résumons ici les recommandations du Comité neuroblastome de la Société Française de lutte contre les Cancers et les leucémies de l’Enfant et de l’adolescent (SFCE) pour le traitement des patients porteurs d’un neuroblastome de haut risque en rechute/progression en France. Ces recommandations concernent la chimio-immunothérapie, l’association d’inhibiteurs d’ALK avec la chimiothérapie et les options de traitement de consolidation en l’absence de progression tumorale, ainsi que la place d’essais thérapeutiques précoces.</div></div><div><div>The prognosis for patients with high-risk neuroblastoma in the event of disease relapse/progression after first line therapy remains poor. However, over the past decade, new therapies have emerged that offer physicians, families and patients the hope of tumor control and, in some cases, a cure. Given the rapid evolution of new therapies in this field, it is strongly recommended that such cases be discussed at a multidisciplinary level and with patients/families regarding treatment options based on existing data. We summarize here the recommendations of the Neuroblastoma Committee of the Société Française de lutte contre les Cancers et les leucémies de l’Enfant et de l’adolescent (SFCE) for the treatment of patients with high-risk neuroblastoma in relapse/progression in France. These recommendations concern chemoimmunotherapy, the combination of ALK inhibitors with chemotherapy, and consolidation treatment options in the absence of tumor progression, as well as the place for early clinical trials.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages 1035-1044"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repotrectinib dans les cancers avancés avec fusions de NTRK après progression ou non sous un premier inhibiteur de TRK","authors":"Léo Ventelou ,&nbsp;Stéphane Vignot","doi":"10.1016/j.bulcan.2025.03.008","DOIUrl":"10.1016/j.bulcan.2025.03.008","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages 927-929"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tislélizumab plus chimiothérapie dans les carcinomes épidermoïdes de l’œsophage et adénocarcinomes œsogastriques HER2 négatifs PD-L1 positifs avancés","authors":"Mélanie Debiais,&nbsp;Alice Boilève","doi":"10.1016/j.bulcan.2025.03.017","DOIUrl":"10.1016/j.bulcan.2025.03.017","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages 925-926"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sommaire","authors":"","doi":"10.1016/S0007-4551(25)00315-7","DOIUrl":"10.1016/S0007-4551(25)00315-7","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages v-vi"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145004396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mort médicalement provoquée en Union Européenne et en Suisse : divergences et ressemblances, questions éthiques","authors":"Elisabeth Lucchi ,&nbsp;Stéphanie Träger ,&nbsp;Antoine Fleury ,&nbsp;Agnès Moura","doi":"10.1016/j.bulcan.2025.03.018","DOIUrl":"10.1016/j.bulcan.2025.03.018","url":null,"abstract":"<div><div>Un projet de loi relatif à « l’accompagnement des malades et de la fin de vie » a été présenté en 2024 en France et débattu par les députés en première lecture. Le premier volet était relatif « aux soins d’accompagnement et aux droits des malades », le second volet à « l’aide active à mourir ». La dissolution de l’Assemblée Nationale en juin 2024, en a interrompu l’examen. Nous revenons d’abord sur l’évolution des textes encadrant les soins palliatifs en France, de la circulaire Laroque en 1986 jusqu’à la loi Claeys-Léonetti, actuellement en vigueur. Dans un deuxième temps, nous développons les textes des différents pays de l’Union Européenne, concernant la fin de la vie, les définitions et les procédures, ainsi que les points significatifs qui les différencient. Puis nous synthétisons l’évolution des demandes dans ces pays. Nous présentons enfin les principaux enjeux éthiques.</div></div><div><div>À draft law on ‘support for the sick and the end of life’ was presented in 2024 in France and debated by the deputies at first reading. The first part concerned ‘supportive care and the patients’ rights’, while the second concerned “active assistance in dying’. With the dissolution of the National Assembly in June 2024, discussion of the proposed law has been suspended. In this summary, we review the development of the legislation governing palliative care in France, from the Laroque circular in 1986 to the Claeys-Léonetti law currently in force. Secondly, we develop the legislation and texts of the various countries of the European Union concerning the end of life, definitions and significant points that differentiate them, as well as the evolution of requests in these countries. Finally we present some ethical concerns.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages 1008-1023"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fin de vie : entendre les craintes","authors":"Manuel Rodrigues","doi":"10.1016/j.bulcan.2025.05.003","DOIUrl":"10.1016/j.bulcan.2025.05.003","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 9","pages":"Pages 937-938"},"PeriodicalIF":0.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144251314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TRANSFORM-O : une nouvelle formation à la recherche translationnelle proposée par la Société Française du Cancer (SFC) et le Collège national des enseignants en cancérologie (CNEC)","authors":"Stanislas Quesada ,&nbsp;Camille Tlemsani ,&nbsp;Christophe Massard ,&nbsp;Manuel Rodrigues","doi":"10.1016/j.bulcan.2025.06.011","DOIUrl":"10.1016/j.bulcan.2025.06.011","url":null,"abstract":"&lt;div&gt;&lt;div&gt;La recherche translationnelle, pont entre recherche fondamentale et clinique, constitue un élément crucial de l’innovation en oncologie. Cependant, son intégration dans la formation des internes reste peu structurée. Le programme TRANSFORM-O a ainsi été développé par la Société française du cancer en association avec le Collège national des enseignants en cancérologie afin d’initier des internes en oncologie à la conception d’essais cliniques intégrant une dimension translationnelle. Seize internes en oncologie ont participé à ce séminaire &lt;em&gt;via&lt;/em&gt; un compagnonnage par quinze experts spécialistes de domaines distincts. Les internes ont été répartis en groupes de quatre selon quatre thématiques : biomarqueurs innovants, phases précoces, radiomique et immunothérapie. Le programme s’est déroulé sur un week-end, avec des temps dédiés à la formation, à l’élaboration du projet de recherche et à une restitution orale. Chaque groupe a conçu un projet collaboratif de recherche clinique fictif associé à un projet de recherche translationnelle ancillaire. Une évaluation par questionnaire (échelle de Likert) a été réalisée à l’issue du programme. Le taux de satisfaction global de ce projet était élevé (4,80 et 4,72 sur cinq, internes et seniors, respectivement). Cette initiative a donc montré la faisabilité et la pertinence d’une initiation précoce à la recherche translationnelle en Cancérologie. Elle pourrait être adaptée à d’autres spécialités médicales. L’impact de cette formation ponctuelle sur le parcours professionnel des internes nécessitera d’être évalué, notamment son applicabilité à un public plus large.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;Translational research, a bridge between basic and clinical research, is a key component of innovation in oncology. However, its integration into medical residency training remains poorly structured. The TRANSFORM-O program was therefore developed by the Société Française du Cancer in association with the Collège National des Enseignants en Cancérologie to introduce oncology residents to the design of clinical trials incorporating a translational research component. Sixteen oncology residents have attended this seminar through mentorship by fifteen experts from various specialties. The residents were divided into four groups according to four predefined topics: innovative biomarkers, early-phase trials, radiomics, and immunotherapy. The program took place over a weekend and included dedicated sessions for training, project development, and oral presentations. Each group designed a collaborative, fictitious clinical research project combined with an ancillary translational research component. A post-program evaluation was conducted using a Likert scale questionnaire. The overall satisfaction level with the program was high (4.80 and 4.72 out of five; residents and mentors, respectively). This initiative demonstrated both the feasibility and relevance of early exposure to translational research in oncology. It could","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1135-1141"},"PeriodicalIF":0.8,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144982410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEPT2 provides new perspective for in-depth analysis of oncology","authors":"Chaoyi Qi ,&nbsp;Jian Wang ,&nbsp;Chunhui Sun ,&nbsp;Jing Li","doi":"10.1016/j.bulcan.2025.04.015","DOIUrl":"10.1016/j.bulcan.2025.04.015","url":null,"abstract":"<div><div>Septins are a conserved family of GTP-binding proteins that assemble into cytoskeletal filaments to function in a highly sophisticated and physiologically regulated manner. Septins are highly conserved from yeast to humans and have gradually been accepted as a new class of cytoskeletal proteins. Mammalian septins have several functions in addition to their role in mitosis. They regulate cell polarity, cytoskeletal organization, vesicle trafficking, ciliogenesis and cell-pathogen interactions. At present, 13 septins have been identified from human. The human septins are classified into four groups based on sequence homology: SEPT2 (SEPT1, 2, 4, 5), SEPT3 (SEPT3, 9, 12), SEPT6 (SEPT6, 8, 10, 11, 14) and SEPT7 (SEPT7) groups. SEPT2, a member of the septin family, is involved in diverse cellular processes. These include the cell stiffness and plasma membrane rigidity observed in yeast, the chromosome segregation, microtubule regulation, and actin dynamics, and also the cytokinesis occurring in mammalian cells. SEPT2 plays a crucial role in tumorigenesis and tumor development. This review summarizes the current knowledge about the role of SEPT2 in tumors and supports its potential as a biomarker for certain types of tumors. After in-depth analysis, it provides new perspectives for oncology.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1142-1149"},"PeriodicalIF":0.8,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vestibulopathies et cancers de l’adulte : revue de la littérature","authors":"Charles Maquet ,&nbsp;Caroline Crampon ,&nbsp;Alexandre Tendron ,&nbsp;Fabrice Giraudet ,&nbsp;Francois Regis Ferrand ,&nbsp;Julien Horion ,&nbsp;Rafik Nebbache ,&nbsp;Frederic Crampon ,&nbsp;Sophie Deneuve","doi":"10.1016/j.bulcan.2025.03.006","DOIUrl":"10.1016/j.bulcan.2025.03.006","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Contexte&lt;/h3&gt;&lt;div&gt;Les thérapeutiques utilisées au cours du cancer peuvent être responsables d’ototoxicité vestibulaire, d’autant plus difficile à détecter que nausées et vomissements sont fréquents chez des patients soumis à une fatigue et un stress important. Un diagnostic approprié permet de corriger au mieux les symptômes, de limiter le risque de chute et d’améliorer la qualité de vie.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Matériel et méthodes&lt;/h3&gt;&lt;div&gt;Après un rappel synthétique sur l’anatomie, la physiologie et les principes de l’exploration du vestibule, une revue narrative des principales vestibulopathies rencontrées chez les patients traités pour un cancer est effectuée, en détaillant leur exploration puis les traitements anticancéreux responsables d’ototoxicité vestibulaire.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Principales données retenues&lt;/h3&gt;&lt;div&gt;L’ototoxicité vestibulaire des traitements systémiques se présente le plus souvent comme une vestibulopathie bilatérale chronique. Les explorations fonctionnelles vestibulaires permettent de différencier les atteintes centrales et périphériques, de quantifier les atteintes et d’orienter vers un bilan d’imagerie. Les sels de platines sont les principaux agents pourvoyeurs d’ototoxicité cochléaire, leurs mécanismes de toxicité sur le vestibule restent flous. Des cas d’ototoxicité vestibulaire sont décrits dans les immunothérapies par inhibiteurs de &lt;em&gt;checkpoint&lt;/em&gt;. La radiothérapie et les invasions tumorales directes peuvent aussi provoquer des atteintes vestibulaires. L’ensemble des altérations vestibulaires est pourvoyeur de chute, notamment chez la personne âgée. Un bilan vestibulaire par un oto-rhino-laryngologiste est indiqué ; le traitement repose habituellement sur la rééducation vestibulaire.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Un circuit entre oncologue et oto-rhino-laryngologiste est capital pour l’exploration de la fonction vestibulaire lors des traitements de cancer avec un potentiel ototoxique.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Context&lt;/h3&gt;&lt;div&gt;Therapeutics used in cancer treatment can cause vestibular ototoxicity, which is particularly challenging to detect due to the frequent occurrence of nausea and vomiting in patients experiencing significant fatigue and stress. An appropriate diagnosis enables optimal symptom correction, reduces the risk of falls, and improves quality of life.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;Following a concise overview of the anatomy, physiology, and principles of vestibular exploration, a narrative review of the primary vestibulopathies encountered in cancer patients is conducted. This review details their exploration and the anti-cancer treatments responsible for vestibular ototoxicity.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Key findings&lt;/h3&gt;&lt;div&gt;Vestibular ototoxicity from systemic treatments typically presents as chronic bilateral vestibulopathy. Vestibular functional tests differentiate between central and peripheral lesions, quantify the damage, and guide imaging assessments. Platinum","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 10","pages":"Pages 1183-1192"},"PeriodicalIF":0.8,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}